entete

Les publications du Dr Sébastien Bonnet

2019

  1. Nickel NP, Yuan K, Dorfmuller P, Provencher S, Lai YC, Bonnet S, Austin ED, Koch CD, Morris A, Perros F, Montani D, Zamanian RT, de Jesus Perez VA. Beyond the lungs: systemic manifestations of pulmonary arterial hypertension. Am J Respir Crit Care Med. 2019 Sep 12. 
  2. Bonnet S, Boucherat O, Paulin R, Wu D, Hindmarch CCT, Archer SL, Song R, Moore JB 4th, Provencher S, Zhang L, Uchida S. Clinical values of non-coding RNAs in cardiovascular, pulmonary, and muscle diseases. Am J Physiol Cell Physiol. 2019 Sep 4.
  3. Nadeau V, Bonnet S, Paulin R. Letter by Nadeau et al regarding article '' BMPR2 mutant rats develop pulmonary and cardiac characteristics of pulmonary arterial hypertension''. Circulation. 2019 Aug 13;140(7):e286-e287.
  4. Mai V, Guay CA, Perreault L, Bonnet S, Bertoletti L, Lacasse Y, Jardel S, Lega JC, Provencher S. Extended anticoagulation for VTE: a systematic review and meta-analysis. Chest. 2019 Jun;155(6):1199-1216. 
  5. Ranchoux B, Nadeau V, Bourgeois A, Provencher S, Tremblay É, Omura J, Coté N, Abu-Alhayja'a R, Dumais V, Nachbar RT, Tastet L, Dahou A, Breuils-Bonnet S, Marette A, Pibarot P, Dupuis J, Paulin R, Boucherat O, Archer SL, Bonnet S, Potus F. Metabolic syndrome exacerbates pulmonary hypertension due to left heart disease. Circ Res. 2019 Aug 2;125(4):449-466.
  6. Bourgeois A, Bonnet S, Breuils-Bonnet S, Habbout K, Paradis R, Tremblay E, Lampron MC, Orcholski ME, Potus F, Bertero T, Peterlini T, Chan SY, Norris KA, Paulin R, Provencher S, Boucherat O. Inhibition of CHK1 (Checkpoint kinase 1) elicits therapeutic effects in pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol. 2019 Aug;39(8):1667-1681.
  7.  Van der Feen DE, Kurakula K, Tremblay E, Boucherat O, Bossers GP, Szulcek R, Bourgeois A, Lampron MC, Habbout K, Martineau S, Paulin R, Kulikowski E, Jahagirdar R, Schalij I, Bogaard HJ, Bartelds B, Provencher S, Berger RMF, Bonnet S, Goumans MJ. Multicenter preclinical validation of BET inhibition for the treatment of pulmonary arterial hypertension. Am J Respir Crit Care Med. 2019 May 1
  8. Omura J, Bonnet S, Kutty S. Right ventricular and pulmonary vascular changes in pulmonary hypertension associated with left heart disease. Am J Physiol Heart Circ Physiol. 2019 May 1;316(5):H1144-H1145
  9. Bonnet S, Paulin R. Involvement of PFKFB3 in pulmonary arterial hypertension pathogenesis. Is it all about glycolysis? Am J Respir Crit Care Med. 2019 Sep 1;200(5):532-534
  10. F Tanguay V, Babin C, Giardetti G, Sohier-Poirier C, Ménard-Cholette V, Ranchoux B, Ruffenach G, Montani D, Bonnet S, Provencher S. Enhanced pulmonary artery radiodensity in Pulmonary Arterial Hypertension: A sign of early calcification? Am J Respir Crit Care Med. 2019 March 15;199(6):799-802
  11. Humbert M, Guignabert C, Bonnet S, Dorfmüller P, Klinger JR, Nicolls MR, Olschewski AJ, Pullamsetti SS, Schermuly RT, Stenmark KR, Rabinovitch M. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J. 2019 Jan 24;53(1).

2018

  1. Humbert M, Guignabert C, Bonnet S, Dorfmüller P, Klinger JR, Nicolls MR, Olschewski AJ, Pullamsetti SS, Schermuly RT, Stenmark KR, Rabinovitch M. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J. 2018 Dec 13. (Epub ahead of print)
  2. Bonnet S, Paulin R, Boucherat O. Small SeP or giant leap for Pulmonary Hypertension Research? Circulation. 2018 Aug 7;138(6):624-626
  3. Guay CA, Morin-Thibault LV, Bonnet S, Lacasse Y, Lambert C, Lega JC, Provencher S. Pulmonary hypertension-targeted therapies in heart failure: A systematic review and meta-analysis. Plos One. 2018 Oct 11;13(10):e0204610
  4. Bourgeois A, Omura J, Habbout K, Bonnet S, Boucherat O. Pulmonary arterial hypertension: New pathophysiological insights and emerging therapeutic targets. Int J Biochem Cell Biol. 2018 Sep 3;104:9-13.
  5. Lajoie AC, Bonnet S, Lacasse Y, Lega JC, Provencher S. Interpreting risk reduction in clinical trials for pulmonary arterial hypertension. Eur Respir Rev. 2018 May 15;27(148).
  6. Agarwal S, Spiekerkoetter E, Austin ED, de Jesus Perez V, Dezfulian C, Maron BA, Ryan JJ, Starks MA, Yu PB, Bonnet S, Perman SM. Career Development of Young Physician-Scientists in the cardiovascular sciences: Perspective and advice from the early career committee of the Cardiopulmonary, Critical Care, and Resuscitation of the American Heart Association. Circ Res. 2018 May 11;122(10):1330-1333.
  7. Provencher S, Archer SL, Ramirez FD, Hibbert B, Paulin R, Boucherat O, Lacasse Y, Bonnet SStandards and methodological rigor in pulmonary arterial hypertension preclinical and translational researchCirculation Research. 2018 Mar 30;122(7):1021-1032
  8. Adao R, Mendes-Ferreira P, Santos-Ribeiro D, Maia-Rocha C, Pimentel L, Pinto C, Mulvaney EP, Reid HM, Kinsella BT, Potus F, Breuils-Bonnet S, Rademaker MT, Provencher S, Bonnet S, Leite-Moreira A, Bras-Silva C. Urocortin-2 improves right ventricular function in pulmonary arterial hypertension. Cardiovascular Research 2018: Jul 1;114(8):1165-1177.
  9. Kuebler WM, Bonnet S, Tabuchi A. Inflammation and autoimmunity in pulmonary hypertension- is there a role for endothelial adhesion molecules? Pulmonary Circulation 2018 Apr-Jun;8(2):2045893218757596
  10. Bonnet S and Boucherat O. The ROS controversy in hypoxic pulmonary hypertension revisited. Eur Respir J. 2018 Mar 8;51(3). pii:1800276
  11. Chen KH, Dasgupta A, Lin J, Potus F, Bonnet S, Iremonger J, Fu J, Mewburn J, Wu D, Dunhan-Snary K, Theilmann AL, Jing ZC, Hindmarch C, Ormiston ML, Lawrie A, Archer SL. Epigenetic dysregulation of the Drp1 binding partners MiD49 and MiD51 increases mitotic mitochondrial fission and promotes pulmonary arterial hypertension: mechanistic and therapeutic implications. Circulation 2018 Jul 17;138(3):287-304.
  12. Boucherat O, Peterlini T, Bourgeois A, Nadeau V, Breuils-Bonnet S, Boilet-Molez S, Potus F, Meloche J, Chabot S, Lambert C, Tremblay E, Chae YC, Altieri DC, Sutendra G, Michelakis ED, Paulin R, Provencher S, Bonnet SMitochondrial HSP90 accumulation promotes vascular remodeling in pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine. 2018 Jul 1;198(1):90-103.
  13. Ranchoux B, Harvey LD, Ayon RJ, Babicheva A, Bonnet S, Chan SY, Yuan JX, Perez VJ. Endothelial dysfunction in pulmonary arterial hypertension: an evolving landscpae (2017 Grover Conference Series)Pulmonary Circulation. 2018 Jan-Mar;8(1):2045893217752912
  14. Zabini D, Granton E, Hu Y, Miranda MZ, Weichelt U, Breuils-Bonnet S, Bonnet S, Morrell NW, Connelly KA, Provencher S, Ghanim B, Klepetko W, Olschewski A, Kapus A, Kuebler WM. Loss of SMAD3 promotes vascular remodeling in pulmonary arterial hypertension via MRTF disinhibition. Am J Respir Crit Care Med. 2018 Jan 15;197(2):244-260.
  15. Frump AL, Bonnet S, de Jesus Perez VA, Lahm T. The emerging role of angiogenesis in adaptive and maladaptive right ventricular remodeling in pulmonary hypertensionAm J Physiol Lung Cell Mol Physiol. 2018 Mar 1;314(3):L443-L460.
  16. Nadeau V, Potus F, Boucherat O, Paradis R, Tremblay E, Iglarz M, Paulin R, Bonnet S, Provencher S. Dual ETA/ETB blockade with macitentan improves both vascular remodeling and angiogenesis in pulmonary arterial hypertension. Pulmonary Circulation. 2018 Jan-Mar;8(1)
  17. Bourgeois A, Lambert C, Habbout K, Paquet-Marceau S, Trinh I, Breuils-Bonnet S, Paradis R, Nadeau V, Paulin R, Provencher S, Bonnet S, Boucherat O. FOXM1 promotes pulmonary smooth muscle cell expansion in pulmonary arterial hypertension. J Mol Med (Berl) 2018 Feb;96(2):223-235. 

2017

  1. Lajoie AC, Guay CA, Lega JC, Lauzière G, Simard S, Lambert C, Lacasse Y, Bonnet S, Provencher S. Trial duration and risk reduction in combination therapy trials for pulmonary arterial hypertension: A systematic review. Chest. 2017 Nov 23.
  2. Malenfant S, Brassard P, Paquette M, Le Blanc O, Chouinard A, Nadeau V, Allan PD, Tzeng YC, Simard S, Bonnet S, Provencher S. Compromised cerebrovascular regulation and cerebral oxygenation in pulmonary arterial hypertension. J Am Heart Assoc. 2017 Oct 12;6(10)
  3. Boucherat O, Provencher S, Bonnet S.Therapeutic Value of ASK1 in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 2017 Sep 20
  4. Boucherat O, Chabot s, Paulin R, Trinh I, Bourgeois A, Potus F, Lampron MC, Lambert C, Breuils-Bonnet S, Nadeau V, Paradis R, Goncharova EA, Provencher S, Bonnet S. HDAC6: A novel histone deacetylase implicated in pulmonary arterial hypertension. Sci. Rep. 2017 Jul 3;7(1):4546
  5. Lajoie AC, Bonnet S, Provencher S. Clinical trial research in focus: improving drug development ad trial design in pulmonary arterial hypertension. Lancet Respir Med. 2017 Jul;5(7):544-546
  6. Lajoie AC, Bonnet S, Provencher S. Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges. Pulm Circ. 2017 Apr-Jun;7(2):312-325
  7. Boucherat O, Vitry G, Trinh I, Paulin R, Provencher S, Bonnet S. The cancer theory of pulmonary arterial hypertension. Pulm. Circ. 2017 Apr-Jun;7(2):285-289
  8. Meloche J, Lampron MC, Nadeau V, Maltais M, Potus F, Lambert C, Tremblay E, Vitry G, Breuils-Bonnet S, Boucherat O, Charbonneau E, Provencher S, Paulin R, Bonnet S. Implication of inflammation and epigenetics Readers in Coronary Artery Remodeling in patients with pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol. 2017 Aug;37(8):1513-1523. 
  9. Perros F, Humbert M, Nazzareno G, Simmoneau G, Bogaard HJ, de Man F, Antigny F, Provencher S, Bonnet S, Galiè N, Humbert M.. Use of beta-blockers in pulmonary hypertensionCirculation: Heart Failure. 2017 Apr;10(4) pii:e003703
  10. Hong Z, Chen K, Dasgupta A, Potus F, Dunham-Snary K, Bonnet S, Tian L, Fu J, Breuils-Bonnet S, Provencher S, Archer SL. miR-138 and miR-125 downregulate MCU, causing pulmonary arterial hypertension's cancer phenotype. Am J Resp Crit Care Med. 2017 Feb 15; 195(4):515-529 (Epub2016 Sep 20)
  11. Chun HJ, Bonnet S, Chan SY. Translating microRNA biology in pulmonary hypertension: it will take more than ''miR'' words. Am J Resp Crit Care Med.  2017 Jan;195(2):167-78 (Epub 2016 Sep 20)
  12. Bonnet S, Provencher S, Guignabert C, Perros F, Boucherat O, Schermuly RT, Hassoun PM, Rabinovitch M, Nicolls MR, Humbert M. Translating research into improved patient care in pulmonary arterial hypertension. Am J Resp Crit Care Med. 2017 Mar1;195(5):583-85 (Epub 2016 Sep 20)

2016

  1. Boucherat O, Bonnet S and Paulin R. The HIPPO-thesis of pulmonary HYPERtension. Am J Resp Crit Care Med. 2016 Oct 1;194(7):787-9
  2. Ranchoux B*, Meloche J*, Paulin R, Boucherat O, Provencher S, Bonnet S. DNA damage and pulmonary hypertension. International Journal of Molecular Sciences. 2016 Jun 22;17(6).
  3. Bonnet S and Provencher S. Shear stress maladaptation in pulmonary arterial hypertension: an ageless concept. Am J Resp Crit Care Med.2016 Jun 15;193(12):1331-2
  4. Boucherat O, Bonnet S. MicroRNA signature of End-Stage idiopathic pulmonary arterial hypertension: Clinical correlations and regulation of WNT signaling. Journal of Molecular Medicine (Berlin). 2016 Aug;94(8):849-51
  5. Ruffenach*, Chabot S*, Tanguay VF, Courboulin A, Boucherat O, Potus f, Meloche J, Pflieger A, Breuils-Bonnet S, Nadeau V, Paradis R, Girerd B, Hautefort A, Montani D, Fadel E, Dorfmuller P, Humbert M, Perros F, Paulin R, Provencher S, Bonnet S. RUNX2 in proliferative and calcified vascular lesions seen in pulmonary arterial hypertension. Am J Resp Crit Care Med. 2016 Nov15;194(10):1273-1285
  6. Lajoie AC, Lauzière G, Lega JC, Lacasse Y, Martin S, Simard S, Bonnet S, Provencher S. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respi Med. 2016 Apr;4(4):291-305
  7. Antigny F, Hautefort A, Meloche J, Belacel-Ouari M, Manoury B, Rucker-Martin C, Péchoux C, Potus F, Nadeau V, Tremblay E, Ruffenach G, Bourgeois A, Dorfmuller P, Breuils-Bonnet S, Fadel E, Ranchou B, Jourdon P, Girerd B, Montani D, Provencher S, Bonnet S, Simmoneau G, Humbert M, Perros F. Potassium-channel subfamily K-member 3 (KCNK3) contributes to the development of pulmonary arterial hypertension. Circulation. 2016 April 5;133 (14):1371-85
  8. Boucherat O, Morissette MC, Provencher S, Bonnet S, Maltais F. Bridging lung development with COPD: Relevance of developmental pathways in COPD pathogenesis. Am J Respir Crit Care Med. 2016 Feb 15;193(4):362-75
  9. Courboulin A, Ranchoux B, Cohen-Kaminsky S, Perros F, Bonnet S. MicroRNA networks in pulmonary arterial hypertension: share mechanisms with cancer? Curr Opin Oncol. 2016 Jan;28(1):72-82

2015

  1. Potus F, Le guen M, Provencher S, Meloche J, Bonnet S. DNA damage at the dawn of micro-RNA pathway impairment in pulmonary arterial hypertension. RNA & DISEASE 2015 (2) :e810
  2. Boucherat O, Potus F, Bonnet S. microRNA and Pulmonary Hypertension. Adv Exp Med Biol. 2015;888:237-52
  3. Perros F, Bonnet S. Bone morphogenetic protein receptor type II and inflammation are bringing old concepts into the new pulmonary arterial hypertension world. Am J Respir Crit Care Med. 2015 Oct 1;192(7):777-9
  4. Fabrice A, Benoît R, Valérie N, Lau E, Sébastien B, Frédéric P. A simple method to assess in vivo proliferation in lung vasculature with EdU: The case of MMC-induced PVOD in rat. http://www.ncbi.nlm.nih.gov/pubmed/26345623Anal Cell Pathol (Amst). 2015;2015:32638. Epub 2015 Aug 9.
  5. Boucherat O, Chabot S, Antigny F, Perros F, Provencher S, Bonnet S. Potassium channels in pulmonary arterial hypertension. Eur Respir J. 2015 Oct;46(4):1167-77. Review.
  6. Meloche J, Potus F, Vaillancourt M, Bourgeois A, Johnson IH, Deschamps L, Chabot S, Ruffenach GN, Henry S, Breuils-Bonnet S, Tremblay È, Nadeau V, Lambert CM, Paradis R, Provencher S, Bonnet S. Bromodomain Containing Protein-4: The epigenetic origin of pulmonary arterial hypertension. Circ Res. 2015 Aug 28;117(6):525-35.
  7. Potus F, Ruffenach G, Dahou A, Thebault C, Breuils-Bonnet S, Tremblay È, Nadeau V, Paradis R, Graydon C, Wong R, Johnson I, Paulin R, Lajoie AC, Perron J, Charbonneau E, Joubert P, Pibarot P, Michelakis ED, Provencher S, Bonnet S. Downregulation of miR-126 contributes to the failing right ventricle in pulmonary arterial hypertension. Circulation. 2015 Sep 8;132(10):932-43.
  8. Meloche J, Le Guen M, Potus F, Vinck J, Ranchoux B, Johnson I, Antigny F, Tremblay E, Breuils-Bonnet S, Perros F, Provencher S, Bonnet S. MiR-223 reverses experimental pulmonary arterial hypertension. Am J Physiol Cell Physiol. 2015 Sep 15;309(6):c363-72.
  9. Courboulin A, Kang C, Baillard O, Bonnet S, Bonnet P. Increasing pulmonary artery pulsatile flow improves hypoxic pulmonary hypertension in piglets. J Vis Exp. 2015 May 11;(99). Vidéo
  10. Malenfant S, Potus F, Mainguy V, Leblanc È, Malenfant M, Ribeiro F, Saey D, Maltais F, Bonnet S, Provencher S. Impaired skeletal muscle oxygenation and exercise tolerance in pulmonary hypertension. Med Sci Sports Exerc. 2015 nov;47(11):2273-82
  11. Sutendra G, Bonnet S. The iron paradigm of pulmonary arterial hypertension: popeye knows best. Circ Res. 2015 May 8;116(10):1636-8.
  12. Boucherat O, Bonnet S. NOGGIN: a new therapeutic target for PH? Focus on “Noggin inhibits hypoxia-induced proliferation by targeting store-operated calcium entry and TRPC channels”. Am J Physiol Cell Physiol. 2015 Jun1;308(11):C867-8
  13. Vaillancourt M, Ruffenach G, Meloche J, Bonnet S. Adaptation and remodelling of the pulmonary circulation in pulmonary hypertension. Can J Cardiol. 2015 Apr;31(4):407-15. Review
  14. Malenfant S, Potus F, Fournier F, Breuils-Bonnet S, Pflieger A, Bourassa S, Tremblay È, Nehmé B, Droit A, Bonnet S, Provencher S. Skeletal muscle proteomic signature and metabolic impairment in pulmonary hypertension. J Mol Med (Berl). 2015 May;93(5):573-84.
  15. Paulin R, Sutendra G, Gurtu V, Dromparis P, Haromy AS, Provencher S, Bonnet S, Michelakis E. A miR-208-Mef2 axis drives the de-compensation of right ventricular function in Pulmonary Hypertension. Circ Res. 2015;116(1):56-69.
  16. Meloche J, Paulin R, Provencher S, Bonnet S. Therapeutic potential of microRNA modulation in pulmonary arterial hypertension. Curr Vasc Pharmacol. 2015;13(3):331-40

2014

  1. Paulin R, Dromparis P, Sutendra G, Gurtu V, Zervopoulos S, Bowers L, Haromy A, Webster L, Provencher S, Bonnet S, Michelakis ED. Sirtuin 3 deficiency is associated with inhibited mitochondrial function and pulmonary arterial hypertension in rodents and humans. Cell Metab. 2014 Nov 4;20(5):827-39.
  2. Sharma S, Umar S, Potus F, Iorga A, Wong G, Meriwether D, Breuils-Bonnet S, Mai D, Navab K, Ross D, Navab M, Provencher S, Fogelman AM, Bonnet S, Reddy ST, Eghbali M. Apolipoprotein A-I Mimetic Peptide 4F Rescues Pulmonary Hypertension by Inducing MicroRNA-193-3p. Circulation 2014; 130(9): 776-85.
  3. Potus F, Malenfant S, Graydon C, Mainguy V, Tremblay E, Breuils-Bonnet S, Ribeiro F, Porlier A, Maltais F, Bonnet S, Provencher S. Impaired angiogenesis and peripheral muscle microcirculation loss contribute to exercise intolerance in pulmonary arterial hypertension. Am J Respir Crit Care Med 2014; 190(3): 318-28.
  4. Meloche J, Pflieger A, Vaillancourt M, Paulin R, Potus F, Zervopoulous S, Graydon C, Courboulin A, Breuils-Bonnet S, Tremblay E, Couture C, Michelakis ED, Provencher S, Bonnet S. Role for DNA damage signaling in pulmonary arterial hypertension. Circulation 2014: 129(7): 786-97.
    Titulaire du "Sir John Vane Award" pour la meilleure publication récente en lien avec les maladies vasculaires pulmonaires.
  5. Paulin R, Meloche J, Courboulin A, Lambert C, Haromy A, Courchesne A, Bonnet P, Provencher S, Michelakis ED, Bonnet S. Targeting cell motility in pulmonary arterial hypertension. Eur Respir J. 2014; 43(2): 531-44.
  6. Meloche J, Pflieger A, Vaillancourt M, Graydon C, Provencher S, Bonnet S. miRNAs in PAH: biomarker, therapeutic target or both? Drug Discovery Today 2014; 19(8): 1264-9.
  7. Potus F, Graydon C, Provencher S, Bonnet S. Vascular remodeling process in pulmonary arterial hypertension with focus on miR-204 and miR126. Pulm Circ 2014; 4(2): 175-84.
  8. Rival G, Lacasse Y, Martin S, Bonnet S, Provencher S. Effect of pulmonary arterial hypertension specific therapies on health-related quality of life: a systematic review. Chest 2014; 146(3):1-23.
  9. Mainguy V, Malenfant S, Neyron AS, Saey D, Maltais F, Bonnet S, Provencher S. Alternatives to the six-minute walk test in pulmonary arterial hypertension. PlosOne 2014; 9(8): e103626.

2013

  1. Malenfant S, Neyron AS, Paulin R, Potus F, Meloche J, Provencher S, Bonnet S. Signal transduction pathways in the development of pulmonary arterial hypertension. Pulm Circ. 2013 Apr;3(2):278-293.
  2. Mainguy V, Malenfant S, Neyron AS, Bonnet S, Maltais F, Saey D, Provencher S. Repeatability and responsiveness of exercise tests in pulmonary arterial hypertension. Eur Respir J. 2013 Aug;42(2):425-34 (Corresponding and senior author)
  3. Meloche J, Renard S, Provencher S, Bonnet S. Anti-inflammatory and Immunosuppressive Agents in PAH. In Pharmacotherapy of Pulmonary Hypertension Handbook of Experimental Pharmacology 2013;218:437-476. Publisher Springer-Verlag; Editors Marc Humbert, Oleg V Evgenov, Johannes-Peter Stasch. (co-senior author).
  4. Renard S, Paulin R, Breuils-Bonnet S, Simard S, Pivarot P, Bonnet S, Provencher S. Pim-1: a new biomarker in pulmonary arterial hypertension. Pulmonary Circulation 2013; 3(1): 74-81.
  5. Meloche J, Courchesne A, Barrier M, Carter S, Bisserier M, Paulin R, Lauzon-Joset JF, Breuils-Bonnet S, Tremblay E, Biardel S, Racine C, Couture C, Bonnet P, Majka SM, Deshaies Y, Picard F, Provencher S, Bonnet S.  Critical Role of the Advanced Glycation Endproducts Receptor in Pulmonary Arterial Hypertension Ethiology. J Am Heart Assoc 2013; 2:e005157 doi: 10.1161/JAHA.112.00515
  6. Malenfant S, Margaillan G, Loehr J, Bonnet S, Provencher S. The emergence of new therapeutic targets in pulmonary arterial hypertension: from now to near future. Expert Review of Respiratory Medicine 2013; 7(1): 1-13.
  7. Dromparis P, Paulin R, Sutendra G, Qi AC, Bonnet S, Michelakis ED. Uncoupling protein 2 deficiency mimics the effects of hypoxia and endoplasmic reticulum stress on mitochondria and triggers pseudohypoxic pulmonary hypertensionCirc Res. 2013 Jul 5;113(2):126-36.

2012

  1. Mainguy V, Malenfant S, Neyron AS, Bonnet S, Maltais F, Saey D, Provencher S. Repeatability and responsiveness of exercise tests in pulmonary arterial hypertension. Eur Respir J 2012; [Epub ahead of print]
  2. Paulin R, Meloche J, Bonnet S. STAT3 signaling in pulmonary arterial hypertension. JAK-STAT 2012; 1(4): 1-11.
  3. Courboulin A, Barrier M, Perreault T, Bonnet P, Tremblay VL, Paulin R, Tremblay E, Lambert C, Jacob MH, Bonnet SN, Provencher S, Bonnet SPlumbagin reverses proliferation and resistance to apoptosis in experimental PAH. Eur Respir J. 2012;40(3): 618-629.
  4. Barrier M, Meloche J, Jacob MH, Courboulin A, Provencher S, Bonnet S. Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension. Cell Mol Life Sci 2012; 69: 2805-31.
  5. Provencher S, Bonnet S. Pulmonary arterial hypertension research: Why does it take so long? How can I contribute? Connections 2012; 3(2): 26-7

2011

  1. Courboulin A, Tremblay VL, Barrier M, Meloche J, Jacob MH, Chapolard M, Bisserier M, Paulin R, Lambert C, Provencher S, Bonnet S. Krüppel-like Factor 5 contributes to pulmonary artery smooth muscle proliferation and resistance to apoptosis in human pulmonary arterial hypertension. Respir Res 2011; 12(1):128.
  2. Paulin R, Courboulin A, Meloche J, Mainguy V, Dumas de la Roque E, Saksouk N, Côté J, Provencher S, Sussman MA, Bonnet S. Signal transducers and activators of transcription-3/pim1 axis plays a critical role in the pathogenesis of human pulmonary arterial hypertension. Circulation. 2011;123(11):1205-15.
  3. Courboulin A, Paulin R, Giguère NJ, Saksouk N, Perreault T, Meloche J, Paquet ER, Biardel S, Provencher S, Côté J, Simard MJ, Bonnet S. Role for miR-204 in human pulmonary arterial hypertension. J Exp Med. 2011;208(3):535-48.
  4. Sutendra G, Dromparis P, Bonnet S, HaromyA, McMurtry MS, Bleackley C, Michelakis E. Pyruvate dehydrogenase inhibition by the inflammatory cytokine TNFα contributes to the pathogenesis of pulmonary arterial hypertension. J Mol Med (Berl) 2011; 89(8) :771-83.
  5. Sutendra G; Bonnet S et al. A novel role of reticulon-4 (Nogo) in the mitochondria-endoplasmic reticulum unit and the pathogenesis of pulmonary arterial hypertension. Sci Transl Med 2011; 3(88) : 88ra55.
  6. Paulin R, Meloche J, Jacob MH, Bisserier M, Courboulin A, Bonnet S. Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertensionAm J Physiol Heart Circ Physiol. 2011 Nov;301(5):H1798-809
  7. Meloche J, Paulin R, Courboulin A, Lambert C, Barrier M, Bonnet P, Bisserier M, Roy M, Sussman MA, Agharazii M, Bonnet S. RAGE-dependent activation of the oncoprotein Pim1 plays a critical role in systemic vascular remodeling processes. Arterioscler Thromb Vasc Biol. 2011 Sep;31(9):2114-24

  8. Paulin R, Courboulin A, Barrier M, Bonnet S. From oncoproteins/tumor suppressors to microRNAs, the newest therapeutic targets for pulmonary arterial hypertension. J Mol Med (Berl). 2011 Nov;89(11):1089-101

2010

  1. Lambert CM, Roy M, Meloche J, Robitaille GA, Agharazii M, Richard DE, Bonnet S. Tumor necrosis factor inhibitors as novel therapeutic tools for vascular remodeling diseases. Am J Physiol Heart Circ Physiol. 2010;299(4):H995-1001.
  2. Sutendra G, Bonnet S, Rochefort G, Haromy A, Folmes KD, Lopaschuk GD, Dyck JR, Michelakis ED. Fatty acid oxidation and malonyl-CoA decarboxylase in the vascular remodeling of pulmonary hypertension. Sci Transl Med. 2010;2(44):44ra58.
  3. Lambert CM, Roy M, Robitaille GA, Richard DE, Bonnet S.  HIF-1 inhibition decreases systemic vascular remodelling diseases by promoting apoptosis through a hexokinase 2-dependent mechanism. Cardiovasc Res 2010; 88(1):196-204.
  4. Dumas de la Roque E, Savineau JP, Bonnet S. Dehydroepiandrosterone: A new treatment for vascular remodeling diseases including pulmonary arterial hypertension. Pharmacol Ther 2010;126(2):186-99.

2009

  1. Bonnet S, Paulin R, Sutendra G, Dromparis P, Roy M, Watson KO, Nagendran J, Haromy A, Dyck JR, Michelakis ED. Dehydroepiandrosterone reverses systemic vascular remodeling through the inhibition of the Akt/GSK3-{beta}/NFAT axis. Circulation 2009; 120(13):1231-40.
  2. Van Haaften T, Akabutu J, Bonnet S, Eaton F, Hashimoto K, Kirby B, Haromy A, Michelakis ED, Archer SL, Thebaud B. Intratracheal Mesenchymal Stem Cells Attenuates Oxygen-induced Lung Injury. Am J Respir Crit Care Med 2009; 180(11):1131-42.

2008

  1. Moudgil R, Wu X, Bonnet S, Dyck JRB, Gallin W, Wieland B, Thebaud B, Michelakis ED, Archer SL. Identification of a structurally unique, human oxygen sensitive, voltage-gated potassium (HOSK) channel contained within the collagen 1 alpha gene.
  2. Sawicka M, Dansereau A, Bonnet S, Bland R, Pierce R, Tremblay G, Bourbonnais Y, Eaton F, Wen L, Thébaud B. Protective Effect of Pre-elafin, a Natural Elastase Inhibitor, in Experimental Oxygen-induced Chronic Lung Injury in Newborn Rats.

2007

  1. Koonen DP, Febbraio M, Bonnet S, Nagendran J, Young ME, Michelakis ED, Dyck JR. Increased Glucose Oxidation Attenuates Age-dependent Decreases in Cardiac Performance and Prevents Cardiac Hypertrophy. Circulation. 2007;116(19):2139-47.
  2. Bonnet S, Archer SL. Potassium Channel Diversity in the Pulmonary Arteries and Pulmonary Veins: Implications for regulation of the pulmonary vasculature in health and during pulmonary hypertension. Pharmacol Ther. 2007;115(1):56-69.
  3. Bonnet S, Rochefort G, Sutendra G, Archer SL, Haromy A, Webster L, Hashimoto K, Bonnet SN, Michelakis ED. The nuclear factor of activated T-cells in Pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci U S A. 2007;104(27):11418-23.
  4. McMurtry MS, Bonnet S, Michelakis ED, Bonnet S, Haromy A, Archer SL.. Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin (RATS) study. Am J Physiol Lung Cell Mol Physiol 2007;293 :L233-40.
  5. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, Lee CT, Lopaschuk GD, Puttagunta L, Bonnet S, Harry G, Hashimoto K, Porter CJ, Andrade MA, Thebaud B, Michelakis ED. A Mitochondria- Plasmamembrane K+ Channel Axis as a novel therapeutic target for cancer. Cancer Cell 2007;11(1):37-51).

2006

  1. Dyck JR, Hopkins TA, Bonnet S, Michelakis ED, Young ME, Watanabe M, Kawase Y, Jishage K, Lopaschuk GD. Malonyl CoA Decarboxylase Deletion in Mice Increases Cardiac Glucose Oxidation and Protects the Heart from Ischemic Injury. Circulation. 2006;114 (16):1721-8).
  2. Bonnet S, Michelakis ED, Porter CJ, Andrade-Navarro MA, Thébaud B, Bonnet S, Haromy A, Harry G, Moudgil R, McMurtry MS, Weir EK, Archer SL. An abnormal mitochondrial-HIF-1α-Kv channel pathway disrupts O2-sensing and triggers pulmonary arterial hypertension in fawn-hooded rats: similarities to human PAH. Circulation. 2006 Jun 6;113 (22):2630-41.

2005

  1. Ladha F, Bonnet S, Eaton F, Hashimoto K, Korbutt G, Thébaud B. Sildenafil Improves Alveolar Growth and Pulmonary Hypertension in Hyperoxia-Induced Lung Injury. Am J Respir Crit Care Med. 2005;172(6):750-6.
  2. Archer SL, Michelakis ED, Thébaud B, Bonnet S, Moudgil R, Wu XC, Weir EK. A central role for O2-sensitive K+ channels and mitochondria in the specialized O2-sensing system. 2005 Signaling pathways in acute oxygen sensing. Novartis Found Symp. 2006;272:157-71; discussion 171-5, 214-7.
  3. Mc Murtry S, Archer SL, Bonnet S, Wu X, Haromy A and Michelakis E. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest. 2005;115(6):1479-1491.

Chapitres publiés

  1. Roxane Paulin, Marjorie Barrier and Sebastien Bonnet. New Therapeutics for pulmonary arterial hypertension: do gene therapies have translational values? Future Science. Clin Invest 2011;1(3):363-6.
  2. Paulin Roxane, Eric Dumas De La Roque, and Sebastien Bonnet. DHEA and vascular health and fonctions. DHEA (dehydroepiandrosterone) in Human Health and Aging, DHEA chapters from Dr. Ronald Watson. editor: Taylor and Francis Group 2011. ISBN 9781439838839.
  3. Savineau JP, Bonnet S, Marthan R. Hypoxia-mediated regulation on Ca2+ transients in pulmonary artery smooth muscle cells. (In Hypoxic pulmonary vasoconstriction: cellular and molecular mechanisms) J YUAN, Editor Kluver Academic press 2003.
© 2012 Université Laval. Tous droits réservés